Tubingen, Germany–(ENEWSPF)–February 18, 2016. The administration of FDA-approved synthetic THC (dronabinol) induces death in leukemia cell lines and offers a “low-toxic therapy option” for patients with cancer, according to findings published online in the journal BMC Cancer.
German researchers evaluated the impact of dronabinol on leukemia cells. Investigators reported that synthetic THC displayed “remarkable anti-proliferative as well as pro-apoptopic efficacy … in a broad spectrum of acute leukemia cell lines.” These findings “provide a promising…
